The effects of Resveratrol on PCOS.

The effects of Resveratrol on expression of main ovarian angiogenesis genes (VEGF & HIF-1) & androgene aromatization gene (CYP19) in granolosa cells of PCOS patients and their IVF outcomes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016030126860N1

Enrollment

Registered

2016-03-15

Start date

2016-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome (PCOS). Polycystic ovarian syndrome

Interventions

Intervention 1: For Intervention Group: Resveratrol, Orally 1gr/day (2 Cap.) for 40 days from the beginning of the menstruation cycle till oocyte retrieval. Intervention 2: For Control Group: Placebo

Treatment - Drugs

For Intervention Group: Resveratrol, Orally 1gr/day (2 Cap.) for 40 days from the beginning of the menstruation cycle till oocyte retrieval.

For Control Group: Placebo of Resveratrol, Orally 2 Cap. for 40 days from the beginning of the menstruation cycle till oocyte retrieval.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Infertility with documented PCOS & Hyperandrogenism; 18-40 Y/O; Candidate for IVF Cycle; If have male factor; it must mild to moderate form, not non-obstructive azospermia; If have other female factor; only cervical & tubal factors are acceptable. Exclusion Criteria: FSH>10; Severe endometriosis (Stage III or IV); Coshing Syndrome; Hyperprolactinemia; Thyroid diseases; Ovarian Tumors; Severe male factor like non-Obstructive Azospermia; Steroids & OCP taking History in past 3 months; SLE (Systemic Lupus Erythematosus) & autoimmune diseases; Systemic diseases like Metabolic Syndrome, Hyperlipidemia, Diabetes & cardiovascular diseases; Diseases due to malnutrition & obesity with unknown cause.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CYP19 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;VEGF Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;HIF-1 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;Sexual hormones (Including; FSH, LH, Estradiol, TSH, Prolactin, Progestrone, Testestrone & AMH). Timepoint: Before & After Intervention. Method of measurement: By IFA Method.;Number of retrieved Oocytes. Timepoint: After Intervention. Method of measurement: Count Under Microscope.;Number of retrieved Mature Oocytes (MII). Timepoint: After Intervention. Method of measurement: Count Under Microscope.;Quality of Retrieved Oocytes. Timepoint: After Intervention. Method of measurement: Based on WHO Criteria.;Number of fertilized eggs. Timepoint: After Intervention. Method of measurement: Based on No. of 2PN oocytes.;Fertilization rate. Timepoint: After Intervention. Method of measurement: fertilized egg number devided to retrieved oocyte number.;Number of Cleavage embryos. Timepoint: After Intervention. Method of measurement: Count the Cleavage (8 Cells) embryos.;Cleavage rate. Timepoint: After Intervention. Method of measurement: embryo number devided to fertilized egg number.;High Quality Embryo Rate. Timepoint: After Intervention. Method of measurement: Count the Grade 1&2 of embryo quality.;Chemical Pregnancy Rate. Timepoint: After Intervention. Method of measurement: B-hCG test.;Clinical Pregnancy Rate. Timepoint: After Intervention. Method of measurement: Gestational Sac in Ultrasound.	—

Measure

Time frame

CYP19 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;VEGF Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;HIF-1 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;Sexual hormones (Including; FSH, LH, Estradiol, TSH, Prolactin, Progestrone, Testestrone & AMH). Timepoint: Before & After Intervention. Method of measurement: By IFA Method.;Number of retrieved Oocytes. Timepoint: After Intervention. Method of measurement: Count Under Microscope.;Number of retrieved Mature Oocytes (MII). Timepoint: After Intervention. Method of measurement: Count Under Microscope.;Quality of Retrieved Oocytes. Timepoint: After Intervention. Method of measurement: Based on WHO Criteria.;Number of fertilized eggs. Timepoint: After Intervention. Method of measurement: Based on No. of 2PN oocytes.;Fertilization rate. Timepoint: After Intervention. Method of measurement: fertilized egg number devided to retrieved oocyte number.;Number of Cleavage embryos. Timepoint: After Intervention. Method of measurement: Count the Cleavage (8 Cells) embryos.;Cleavage rate. Timepoint: After Intervention. Method of measurement: embryo number devided to fertilized egg number.;High Quality Embryo Rate. Timepoint: After Intervention. Method of measurement: Count the Grade 1&2 of embryo quality.;Chemical Pregnancy Rate. Timepoint: After Intervention. Method of measurement: B-hCG test.;Clinical Pregnancy Rate. Timepoint: After Intervention. Method of measurement: Gestational Sac in Ultrasound.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojdeh Bahramrezaie

Tehran University of Medical sciences

m-bahramrezaie@razi.tums.ac.ir+98 21 4438 2693

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026